Oorsprong van het eerstegraads netwerk van Christopher Cargill
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Idorsia Pharmaceuticals Japan Ltd.
 Idorsia Pharmaceuticals Japan Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Japan Ltd. is a company based in Tokyo, Japan. The Japanese company's description focuses on a nationwide contest aimed at expressing gratitude to medical professionals and raising awareness about the role of medicine and healthcare in society. The contest is designed to encourage elementary school students to think about their future dreams, their own and their family's health, and a society where everyone can live a healthy life both physically and mentally.
9
| Subsidiary | Pharmaceuticals: Major | 9 |
Sosei R&D Ltd.
 Sosei R&D Ltd. Pharmaceuticals: MajorHealth Technology Sosei R&D Ltd. manufactures pharmaceutical products. It develops and commercializes product opportunities based upon clinical uses for known drugs and templates. The company was founded by Julian Gilbert and Robin Bannister in March, 2000 and is located in Saffron Walden, the United Kingdom.
3
| Subsidiary | Pharmaceuticals: Major | 3 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Christopher Cargill via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| NXERA PHARMA CO., LTD. | Pharmaceuticals: Major | Chief Executive Officer Compliance Officer Director of Finance/CFO Chief Executive Officer Comptroller/Controller/Auditor Public Communications Contact Corporate Officer/Principal | |
Mina (Holdings) Ltd.
 Mina (Holdings) Ltd. Financial ConglomeratesFinance Mina (Holdings) Ltd. is a holding company. The private company is based in London, UK and was founded in 2014. | Financial Conglomerates | Director/Board Member Director/Board Member | |
MiNA Therapeutics Ltd.
 MiNA Therapeutics Ltd. BiotechnologyHealth Technology MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
Heptares Therapeutics Ltd.
 Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| GLAXOSMITHKLINE PHARMACEUTICALS LIMITED | Pharmaceuticals: Major | Director/Board Member | |
| Cranfield University | College/University | Masters Business Admin | |
Jitsubo Co., Ltd.
 Jitsubo Co., Ltd. BiotechnologyHealth Technology Jitsubo Co., Ltd. researches, develops, and produces peptides. It operates as a peptide development company that provides solutions to patients using their proprietary technologies for manufacturing and engineering peptides. The firm specializes in peptide synthesis, which enables users to modify amino acid sequence for the creation of physical, chemical, and pharmacological properties. It also engages in development of peptide pharmaceuticals, licensing regarding active ingredient manufacturing technology for peptides, and peptide drug discovery research. The company was founded by Yusuke Kohno and Kazuhiro Chiba in 2000 and is headquartered in Tokyo, Japan. | Biotechnology | Director/Board Member | |
| University of Bath | College/University | Undergraduate Degree | |
Monash University
 Monash University Other Consumer ServicesConsumer Services Monash University operates as a public research university. It specializes in higher education, global engagement, postgraduate courses, undergraduate study, and PhD research. The company was founded on March 1961 and is headquartered in Clayton, Australia. | College/University | Undergraduate Degree | |
Mizuho Securities Co., Ltd. (Broker)
 Mizuho Securities Co., Ltd. (Broker) Investment Banks/BrokersFinance Mizuho Securities Co., Ltd. (Broker) (Mizuho Securities-Broker) is the brokerage division of Mizuho Securities Co. Ltd., ultimately owned by Mizuho Financial Group, Inc. (TYO: 8411; NYSE: MFG) in Japan. The firm was originally founded in 1917 and is headquartered in Tokyo with a network of offices throughout Japan as well as overseas representation through Mizuho entities or strategic partners (in Great Britain, Switzerland, the US, Hong Kong, Mainland China, South Korea, Singapore and India). Mizuho Securities-Broker provides enhanced equity and fixed income execution services for their clients who includes private individuals in Japan, domestic and foreign institutions, non-financial companies, financial institutions and public corporations in the securities and investment banking fields. | Investment Banks/Brokers | Analyst-Equity | |
| NEC FIELDING LTD | Information Technology Services | Corporate Officer/Principal | |
ILC Therapeutics Ltd.
 ILC Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services ILC Therapeutics Ltd. is a British biotechnology company that conducts research and experimental development. The company is based in Lanarkshire, UK. The company was founded by William H. Stimson. Alan Keith Walker has been the CEO of the company since 2020. | Miscellaneous Commercial Services | Chairman | |
| BIOCON LIMITED | Pharmaceuticals: Major | Chief Executive Officer | |
| Apterna Ltd. | Director/Board Member | ||
| MEREO BIOPHARMA GROUP PLC | Biotechnology | Director/Board Member | |
| INDIVIOR PLC | Pharmaceuticals: Major | Director/Board Member | |
Phase4 Partners Ltd.
 Phase4 Partners Ltd. Investment ManagersFinance Phase4 Ventures ltd (Phase4 Ventures) is a venture capital subsidiary of Nomura International Plc founded in 1999. The firm is headquartered in London, UK. | Investment Managers | Director/Board Member | |
| KROMEK GROUP PLC | Medical Specialties | Director/Board Member | |
| Baines Peter Consulting | Director/Board Member | ||
| SYNGENE INTERNATIONAL LIMITED | Miscellaneous Commercial Services | Chief Executive Officer | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
| The University of Sheffield | College/University | Undergraduate Degree | |
SmithKline Beecham Ltd.
 SmithKline Beecham Ltd. Pharmaceuticals: MajorHealth Technology Smithkline Beecham Ltd. manufacture of basic pharmaceutical products. It also provides mineral water, bottled water, and soft drinks. The company was founded on January 24, 1989 and is headquartered in Brentford, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
| Kyoto Prefectural University of Medicine | College/University | Doctorate Degree |
Statistieken
Internationaal
| Verenigd Koninkrijk | 14 |
| Japan | 5 |
| India | 5 |
| Australië | 3 |
| Verenigde Staten | 2 |
Sectoraal
| Health Technology | 13 |
| Consumer Services | 6 |
| Finance | 4 |
| Commercial Services | 3 |
| Technology Services | 2 |
Operationeel
| Director/Board Member | 31 |
| Corporate Officer/Principal | 6 |
| Chief Executive Officer | 4 |
| Independent Dir/Board Member | 4 |
| President | 3 |
Sterkste connecties
- Beurs
- Insiders
- Christopher Cargill
- Bedrijfsconnecties
